GB201307269D0 - Combination Therapy - Google Patents

Combination Therapy

Info

Publication number
GB201307269D0
GB201307269D0 GBGB1307269.9A GB201307269A GB201307269D0 GB 201307269 D0 GB201307269 D0 GB 201307269D0 GB 201307269 A GB201307269 A GB 201307269A GB 201307269 D0 GB201307269 D0 GB 201307269D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1307269.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PH Therapeutics Ltd
Original Assignee
PH Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PH Therapeutics Ltd filed Critical PH Therapeutics Ltd
Priority to GBGB1307269.9A priority Critical patent/GB201307269D0/en
Publication of GB201307269D0 publication Critical patent/GB201307269D0/en
Priority to PCT/GB2014/051205 priority patent/WO2014174254A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1307269.9A 2013-04-23 2013-04-23 Combination Therapy Ceased GB201307269D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1307269.9A GB201307269D0 (en) 2013-04-23 2013-04-23 Combination Therapy
PCT/GB2014/051205 WO2014174254A2 (en) 2013-04-23 2014-04-17 Combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1307269.9A GB201307269D0 (en) 2013-04-23 2013-04-23 Combination Therapy

Publications (1)

Publication Number Publication Date
GB201307269D0 true GB201307269D0 (en) 2013-05-29

Family

ID=48537633

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1307269.9A Ceased GB201307269D0 (en) 2013-04-23 2013-04-23 Combination Therapy

Country Status (2)

Country Link
GB (1) GB201307269D0 (en)
WO (1) WO2014174254A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
CN114624444A (en) * 2020-12-10 2022-06-14 中国医学科学院基础医学研究所 Use of immunoglobulin IgE in pulmonary hypertension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321855T1 (en) * 1997-01-14 2006-04-15 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTOR 5
GB201118359D0 (en) * 2011-10-25 2011-12-07 Univ Sheffield Pulmonary hypertension
GB201118840D0 (en) * 2011-11-01 2011-12-14 Univ Sheffield Pulmonary hypertension II

Also Published As

Publication number Publication date
WO2014174254A3 (en) 2014-12-24
WO2014174254A2 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
IL263026A (en) Ibrutinib combination therapy
GB201321746D0 (en) Therapeutic agents
GB201321743D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
HK1221164A1 (en) Bacteriophage therapy
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321748D0 (en) Therapeutic agents
GB201321745D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic
GB201321731D0 (en) Therapeutic agents
GB201304872D0 (en) Treatment
GB201310755D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)